Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE (AIO-KRK-0217)
DRKS00018695Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of capecitabine in colon cancer, rectal cancer and rectosigmoid cancer (3 arms), sponsored by Technische Universität Dresden. Started Dec 2019; status: completed.
02
Drugs
capecitabine
03
Conditions
colon cancerrectal cancerrectosigmoid cancer
Beyond the preview
Go deeper on DRKS00018695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00018695.